Abstract
P19-47. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity
Highlights
Recombinant Adenovirus serotype 5 (Ad5) vectors have been used as vaccine platforms to induce cell mediated and humoral immune responses in human clinical studies
This vector has been reported to allow for induction of potent immune responses to transgene antigens in the presence of Ad5 immunity
We previously reported the use of the Ad5 [E1, E2b-] platform to induce cellular immune responses (CMI) against HIV-1 Gag in Ad5 hyper immune mice
Summary
Recombinant Adenovirus serotype 5 (Ad5) vectors have been used as vaccine platforms to induce cell mediated and humoral immune responses in human clinical studies. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity ES Gabitzsch*1, Y Xu1, LH Yoshida1, JP Balint1, A Amalfitano2 and FR Jones1
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
